Complement C1 inhibitor protein - CSL Behring

Drug Profile

Complement C1 inhibitor protein - CSL Behring

Alternative Names: Berinert; Berinert HS; Berinert P; C1 esterase inhibitor - CSL Behring; C1 esterase inhibitor concentrate; C1-INH - CSL Behring; CE 1145; Complement C1 inactivator - CSL Behring; CSL 830; CSL 842; Haegarda; Human C1 esterase inhibitor concentrate

Latest Information Update: 26 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSL Behring
  • Class Complement C1 inactivator proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase III Transplant rejection
  • Discontinued Reperfusion injury; Septic shock; Vascular disorders

Most Recent Events

  • 02 Mar 2018 Adverse events and efficacy data from the phase III COMPACT trial in Hereditary angioedema (SC) presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (AAAAI-2018)
  • 21 Sep 2017 CSL Behring completes a phase III trial for Hereditary angioedema (Prevention of attacks, In adolescent, In children, In adults) in USA, Canada, Australia, Israel and European Union (SC) (NCT02316353)
  • 25 Jul 2017 Launched for Hereditary angioedema (In adolescents, Prevention, In adults) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top